Table 1 Summary of clinicopathological characteristics for five cervical cancer cohorts

From: Integrated analysis of cervical squamous cell carcinoma cohorts from three continents reveals conserved subtypes of prognostic significance

  

Discovery Cohort

Validation Cohorts

 
  

TCGA

Bergen

Innsbruck

Oslo

Uganda

Total

Cohort Numbers

 

236

37

28

248

94

643

Stagea

I Unknown

7 (3%)

0

1 (3.6%)

0

0

8 (1.2%)

 

IA

1 (0.4%)

0

1 (3.6%)

0

0

2 (0.3%)

 

IB

115 (48.7%)

34 (91.9%)

14 (50%)

20 (8.1%)

15 (16.1%)

198 (30.8%)

 

II

54 (22.9%)

2 (5.4%)

6 (21.4%)

162 (65.3%)

45 (47.9%)

270 (42%)

 

III

39 (16.5%)

0

4 (14.3%)

56 (22.6%)

31 (33%)

130 (20.2%)

 

IV

14 (5.9%)

1 (2.7%)

2 (7.1%)

10 (4%)

2 (2.1%)

29 (4.5%)

 

NA

7 (3%)

0

0

0

1 (1.1%)

8 (1.2%)

Age

Median (Range)

47 (20–88)

42 (28–64)

49 (29–91)

54 (22–82)

45 (26–82)

 

HPV Type

16

136 (57.6%)

22 (59.5%)

17 (60.7%)

178 (71.8%)

39 (41.5%)

392 (60.9%)

 

18

26 (11%)

2 (5.4%)

6 (21.4%)

30 (12.1%)

14 (14.9%)

78 (12.1%)

 

45

19 (8.1%)

4 (10.8%)

0

9 (3.6%)

14 (14.9%)

46 (7.2%)

 

Other

55 (23.3%)

9 (24.3%)

5 (17.9%)

31 (12.5%)

27 (28.7%)

127 (19.8%)

HPV Clade

Alpha 7

57 (24.2%)

6 (16.2%)

6 (21.4%)

40 (16.1%)

32 (34%)

141 (21.9%)

 

Alpha 9

172 (72.9%)

29 (78.4%)

20 (71.4%)

194 (78.2%)

54 (57.4%)

469 (72.9%)

 

Other

7 (3%)

2 (5.4%)

2 (7.1%)

14 (%)

8 (8.5%)

33 (5.1%)

Treatmentb

Surgery

NA

18 (48.6%)

5 (17.9%)

0

NA

23 (7.3%)

 

Surgery + Radiotherapy

NA

14 (37.8%)

17 (60.7%)

0

NA

31 (9.9%)

 

Surgery + Radiotherapy + Chemotherapy

NA

5 (13.5%)

6 (21.4%)

0

NA

11 (3.5%)

 

Radiotherapy

NA

0

0

47 (19%)

NA

47 (15%)

 

Radiotherapy + Chemotherapy

NA

0

0

201 (81%)

NA

201 (64.2%)

Survivalc

Median (Range)

1.9 (0−17.5)

8 (1.8−13.2)

9.8 (0.1−23.2)

4.2 (0.3−12.7)

1.1 (0−2.4)

 

Vital status

Alive

181 (76.7%)

32 (86.5%)

16 (57.1%)

187 (75.4%)

42 (44.7%)

458 (71.2%)

 

Dead

55 (23.3%)

5 (13.5%)

12 (42.9%)

61 (24.6%)

52 (55.3%)

185 (28.8%)

Cluster Assignment

C1

175 (74.2%)

32 (86.5%)

24 (85.7%)

198 (79.8%)

69 (73.4%)

498 (77.4%)

 

C2

61 (25.8%)

5 (13.5%)

4 (14.3%)

50 (20.2%)

25 (26.6%)

145 (22.6%)

HIV Status

Positive

NA

NA

NA

NA

59

59

 

Negative

NA

NA

NA

NA

35

35

Available Data

RNA-seq

236

37

NA

NA

94

367

 

Methylation

236

37

28

248

94

643

 

Mutation

236

37

NA

NA

94

367

 

RPPA

137

NA

NA

NA

NA

137

 

Microarray (Illumina WG-6 v3)

NA

NA

NA

137

NA

137

 

Microarray (Illumina HT-12 v4)

NA

NA

NA

109

NA

109

 

Copy number (MeCpG-derived)

236

37

28

248

NA

549

  1. aFurther breakdown of tumour stage is included in Supplementary Data 1 and Supplementary Data 6.
  2. bTreatment breakdown for individual patients is included in Supplementary Data 6.
  3. cOverall survival was recorded for TCGA and Ugandan cohorts, while disease-specific survival was recorded for Bergen, Innsbruck and Oslo cohorts.
Back to article page